Home PI3K/Akt/mTOR Antioxidant chemical Maltol

research use only

Maltol Antioxidant chemical

Cat.No.S4940

Maltol (Larixinic acid, Palatone, Veltol) is a naturally occurring organic compound that is flavour enhancer and flavouring agent.
Maltol Antioxidant chemical Chemical Structure

Chemical Structure

Molecular Weight: 126.11

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S494001 DMSO]25 mg/mL]false]]]false]]]false Purity: 98%
98

Chemical Information, Storage & Stability

Molecular Weight 126.11 Formula

C6H6O3

 Storage (From the date of receipt) 3 years -20°C powder (seal)
CAS No. 118-71-8 -- Storage of Stock Solutions

Synonyms Larixinic acid, Palatone, Veltol Smiles CC1=C(C(=O)C=CO1)O

Solubility

In vitro
Batch:

DMSO : 25 mg/mL (198.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro

Maltol can effectively protect nerve cells against oxidative damage caused by ROS in order to maintain normal physiological functions of cells and inhibit diabetes-induced oxidative stress and irreversible kidney damage[1].
In vivo

For hepatoprotective activity in vivo, pretreatment with maltol (12.5, 25 and 50 mg/kg; 15 days) drastically prevents the elevated activities of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and triglyceride (TG) in serum and the levels of malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) in liver tissue. Meanwhile, the levels of hepatic antioxidant, such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) are elevated by maltol pretreatment, compared to the alcohol group. Maltol pretreatment significantly inhibits alcohol-induced hepatocyte apoptosis and fatty degeneration. It is effective in the prevention of alcohol-induced hepatic damage in mice[1]. Also, maltol is suggested to be a functional agent to prevent the oxidative damage in the brain of mice[2].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05177484 Recruiting
Cancer Colon
The Royal Wolverhampton Hospitals NHS Trust|Norgine
 May 30 2022 Phase 3
NCT05126901 Recruiting
Anemia|Iron-deficiency
Shield Therapeutics
 October 4 2021 Phase 3
NCT04626414 Unknown status
Anemia Iron Deficiency
Shield Therapeutics
 September 28 2020 Phase 1
NCT03774615 Terminated
Heart Failure Left Sided|Anemia Iron Deficiency
Hannover Medical School|Shields Shields and Associates
 March 18 2019 Phase 4
NCT03181451 Completed
Iron Deficiency Anaemia in Children|Iron-Deficiency
Shield Therapeutics|Medpace Inc.
 March 14 2017 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.